KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Phase 1 dosing is expected to finish by the end of 2025
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Subscribe To Our Newsletter & Stay Updated
